Blocking an Endocannabinoid-Degrading Enzyme Relieved Migraine Pain in Mice Without Tolerance

What the researchers found

The MAGL inhibitor ABD-1970 blocked cephalic allodynia in both acute and chronic nitroglycerin-induced migraine models. Repeated daily administration for 5 days did not produce tolerance. MAGL and CB1 receptor mRNA were highly expressed in both the trigeminal ganglia and trigeminal nucleus caudalis, key pain-processing regions for headache.

Why it matters

Migraine affects over 1 billion people worldwide and current treatments often lose effectiveness or have significant side effects. Enhancing the endocannabinoid system by blocking the enzyme that breaks down natural cannabinoids offers a fundamentally different approach that may avoid the tolerance issues seen with direct cannabinoid receptor activation.

The numbers in context

A single ABD-1970 dose blocked acute migraine pain. It also reversed established chronic allodynia. No tolerance after 5 consecutive days. High MAGL and CB1 expression found in trigeminal ganglia and trigeminal nucleus caudalis in both neuronal and non-neuronal cells.

How the study worked

C57BL6/J male and female mice received nitroglycerin (a human migraine trigger) acutely or every other day for 9 days to model chronic migraine. Periorbital allodynia was measured by von Frey hair stimulation. ABD-1970 was tested as a single dose in acute and chronic models and daily for 5 days to assess tolerance. In situ hybridization mapped MAGL and CB1 expression in trigeminal pain circuits.

What this study cannot tell us

Mouse migraine models rely on nitroglycerin-induced pain, which may not capture all aspects of human migraine. Five days of dosing is very short to assess long-term tolerance. The specific inhibitor (ABD-1970) has not been tested in humans.

How to read the evidence

Well-designed mouse study using established migraine models with both acute and chronic paradigms. Results are promising but have not been tested in humans.

When this study was published

Published in 2025.

The bigger picture

Direct cannabis use for migraine carries tolerance risk and side effects. MAGL inhibitors work differently by boosting the body's own endocannabinoids at the exact times and places they are naturally released. The lack of tolerance in this study is particularly encouraging compared to direct CB1 agonists.

Questions still open

• Does the lack of tolerance persist beyond 5 days? Would MAGL inhibition be effective in migraine patients who have not responded to other treatments? How does this approach compare to CBD or THC for migraine?

Common questions

Read the original research

Enhancement of the endocannabinoid system through monoacylglycerol lipase inhibition relieves migraine-associated pain in mice.

The journal of headache and pain, 26(1), 84

Citation

Mangutov, Elizaveta; Awad-Igbaria, Yaseen; Siegersma, Kendra; Gastambide, Francois; Asuni, Ayodeji A; Pradhan, Amynah A A. (2025). Enhancement of the endocannabinoid system through monoacylglycerol lipase inhibition relieves migraine-associated pain in mice.. The journal of headache and pain, 26(1), 84. https://doi.org/10.1186/s10194-025-02029-9

Explore the wider topic

• CBD Oil Quality Guide: How to Avoid Snake Oil
• Anxiety After Quitting Weed: When to Consider Medication
• Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
• Cannabis for Chronic Pain: What the Research Actually Supports
• Cannabis and Epilepsy: The Epidiolex Story and What It Means
• Does CBD Actually Work for Anxiety? What the Evidence Shows
• Does CBD Help with Weed Withdrawal? What Studies Show
• CBD vs THC: The Differences That Actually Matter
• The Proven Medical Benefits of Cannabis: What Research Supports
• Quitting Weed Before Surgery
• Weed and Medications: What Changes When You Quit
• Quitting Weed During Pregnancy: What You Need to Know
• Quitting Weed While Pregnant: What You Need to Know
• Cannabis and Older Adults: Risks Seniors Should Know
• Cannabis and Breastfeeding: THC in Breast Milk